BioDrugs
Abbreviated title (ISO 4) | BioDrugs |
|---|---|
| Discipline | Drug therapy, pharmacology |
| Language | English |
| Edited by | Jamie D. Croxtall |
| Publication details | |
| Publisher | |
Publication history | 1994-present |
| Frequency | 6/year |
| Hybrid | |
| 2.989 | |
| Indexing | |
| ISSN |
1173-8804 (print) 1179-190X (web) |
| CODEN | BIDRF4 |
| Links | |
BioDrugs is a peer-reviewed pharmacology journal.
It has an impact factor of 2.989.[1]
It is published by Adis International (Springer Science + Business Media)
BioDrugs aims to advance discussion and evaluation of the latest developments in the clinical application of biotechnology for the treatment of human disease by providing a programme of review articles and original research covering the most important aspects of biotechnology-based pharmaceuticals, diagnostic products and innovations in bio-tech therapy.
This includes novel drug delivery systems; protein/peptide therapeutics; monoclonal antibodies, antibody fragments and antibody engineering; biosimilars; cytokines and cytokine receptors; recombinant DNA and gene regulation technology; gene therapy; nucleic acid therapeutics and diagnostics; stem cell therapies; drug target validation; glycolated and pegylated therapeutics; and pioneering technologies in drug design and development.
BioDrugs publishes articles on all areas of medicine.
Abstracted/Indexed in:- PubMed/Medline, SCOPUS, EMBASE, Google Scholar, EBSCO, CSA, CAB International, Academic OneFile, Academic Search, ASFA, CAB Abstracts, Current Abstracts, Expanded Academic, Global Health, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions